LAG-3 / CD223 – RMab

IHC of LAG-3 on a FFPE Testicular Carcinoma Tissue

Specification Sheets
Safety Data Sheet


Intended Use For In Vitro Diagnostic Use
Summary and Explanation

Lymphocyte-activation gene 3, also known as LAG-3 and designated as CD223, is a cell surface protein with diverse biologic effects on T cell function encoded by the LAG3 gene. The gene for LAG-3 lies adjacent to the gene for CD4 on human chromosome 12 (12p13) and is approximately 20% identical to the CD4 gene. LAG-3 is expressed on activated T cells, natural killer cells, B cells and plasmacytoid dendritic cells. The LAG-3 protein negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar fashion to CTLA-4 and PD-1 and has been reported to play a role in Treg, regulatory T cells, suppressive function. LAG-3 also helps maintain CD8+ T cells in a tolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG-3 is known to be involved in the maturation and activation of dendritic cells.

Studies have shown that LAG-3 is a prognostic indicator of poor treatment outcomes in chronic lymphocytic leukemia, has been associated with higher risk of multiple myeloma, may play a modulating role in autoimmune diabetes and has been identified in a subset of HIV-specific LAG-3(+) CD8(+) T cells that negatively correlated with plasma viral load. IHC studies have shown LAG-3 expression on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas.

Antibody Type Rabbit Monoclonal Clone EP294
Isotype IgG Reactivity Paraffin, Frozen
Localization Cytoplasmic, Membranous Control Testis, Lymph Node, Spleen, Lymphoblastic Lymphoma, TCC
Presentation LAG-3 is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Catalog No. Antibody Type Dilution Volume/QTY
BSB 3363 Prediluted Ready-To-Use 3.0 ml
BSB 3364 Prediluted Ready-To-Use 7.0 ml
BSB 3365 Prediluted Ready-To-Use 15.0 ml
BSB 3366 Concentrated 1:10-1:50 0.1 ml
BSB 3367 Concentrated 1:10-1:50 0.5 ml
BSB 3368 Concentrated 1:10-1:50 1.0 ml
BSB 3369 Control Slides 5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.

Related products

Skip to content